Loxo Oncology Inc. (LOXO)

132.55
NASDAQ : Health Technology
Prev Close 132.55
Day Low/High 0.00 / 0.00
52 Wk Low/High 42.11 / 138.54
Avg Volume 386.10K
Exchange NASDAQ
Shares Outstanding 30.03M
Market Cap 3.89B
EPS -5.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Noteworthy Tuesday Option Activity: LOXO, MEET, THO

Noteworthy Tuesday Option Activity: LOXO, MEET, THO

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Loxo Oncology, Inc , where a total volume of 2,775 contracts has been traded thus far today, a contract volume which is representative of approximately 277,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 85.6% of LOXO's average daily trading volume over the past month, of 324,305 shares.

Loxo Oncology Stock Sees Short Interest Expand By 11%

Loxo Oncology Stock Sees Short Interest Expand By 11%

The most recent short interest data has been released for the 12/29/2017 settlement date, which shows a 445,280 share increase in total short interest for Loxo Oncology, Inc , to 4,463,652, an increase of 11.08% since 12/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Updated Larotrectinib Pediatric Phase I Clinical Trial Data Demonstrates Response In TRK Fusion Cancers

Updated Larotrectinib Pediatric Phase I Clinical Trial Data Demonstrates Response In TRK Fusion Cancers

- 93 percent overall response rate of 17 pediatric patients with TRK fusion cancers

Nucor, Henry Schein, Kemet, Splunk: 'Mad Money' Lightning Round

Nucor, Henry Schein, Kemet, Splunk: 'Mad Money' Lightning Round

Jim Cramer highlights Nucor, Henry Schein, Kemet, Splunk, and Loxo Oncology.

Give Thanks for This Week: Cramer's 'Mad Money' Recap (Tuesday 11/21/17)

Give Thanks for This Week: Cramer's 'Mad Money' Recap (Tuesday 11/21/17)

Jim Cramer says this is the 'Era of Good Feelings,' the week when despite the bad news, buyers still want to buy and it feels like there's a ban on selling.

Bayer And Loxo Oncology To Develop And Commercialize Two Therapies That Selectively Target Genetic Drivers Of Cancer

Bayer And Loxo Oncology To Develop And Commercialize Two Therapies That Selectively Target Genetic Drivers Of Cancer

- Larotrectinib (LOXO-101) and LOXO-195 target tropomyosin receptor kinase (TRK) fusion proteins, which are a product of genetic alterations that occur across a range of different tumors

Loxo Oncology Stock Sees Short Interest Decrease By 10.5%

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 422,370 share decrease in total short interest for Loxo Oncology, Inc , to 3,617,366, a decrease of 10.46% since 05/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.